Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Kamada, retaining the price target of $11.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andrew Fein has given his Buy rating due to a combination of factors that highlight Kamada’s potential for growth and strategic development. One of the key reasons is the anticipated interim Phase 3 data from the inhaled AAT program, which is expected to be a significant decision point for the company. Although there are challenges with trial enrollment, the management’s efforts to expedite recruitment and their strategic focus on expanding plasma collection centers in the U.S. are seen as positive steps.
Furthermore, Kamada’s active pursuit of business development opportunities, including potential in-licensing, collaborations, or acquisitions by early 2026, is expected to enhance their market portfolio. The company’s recent financial performance, with a notable increase in revenues and adjusted EBITDA, underscores the successful marketing of their diverse product portfolio. These elements combined suggest a robust growth trajectory for Kamada, justifying the Buy rating.
According to TipRanks, Fein is a 5-star analyst with an average return of 24.9% and a 52.49% success rate. Fein covers the Healthcare sector, focusing on stocks such as Alector, Wave Life Sciences, and Palvella Therapeutics.
In another report released on November 3, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a ILA2,519.00 price target.